chandigarh citybased surya pharmaceuticals with net revenue of rs 1144 crore in financial year 200910 has acquired usbased overthecounter otc analgesic drug brand activon along with its global marketing rights for 22 million the activon brand comes to suryas kitty with the acquisition of ameshire investment corp through its whollyowned subsidiary surya pharmaceutical singapore the company will fund the acquisition through a mix of internal accrual and debt financing from exim bank it said in a filing to the bse surya pharma ceo hariom bhatia said the main benefits of this acquisition are the existing brands existing business and established profitability however at the same time through this acquisition we get access to the leading retailers in us like walmart walgreen cvs and riteaid etc this gives us an opportunity to launch some of our own otc and fmcg products in future through those shelf spaces he was hopeful of introducing the range of products under suryas label within a yearbhatia said in the last fiscal activon used to treat aches and pains achieved total top line of usd 85 million with an ebitda of almost 32 this is expected to grow up to usd 18 to 20 million in coming financial year the whole profit is expected to come in to the kitty of surya pharmatalking about the benefits of deal he said in another six months we will be able to achieve topline of about usd 56 million but next year activon alone is going to contribute more than usd 20 million because besides the growth in us we will also launch this product in india and other markets as well